A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.

ABSTRACT:

Purpose

Theranostics integrates diagnostic imaging (e.g., ¹⁸F-PSMA-1007 PET) with targeted radioligand therapy (TRT; e.g., ¹⁷⁷Lu-PSMA-617), but personalized dosimetry remains challenging due to complex dose calculations. Current methods like Monte Carlo simulations are accurate but require impractical post-treatment multi-day SPECT/CT imaging. Here we establish a proof-of-concept framework using pre-treatment PET/CT to predict TRT doses via graphical analysis and Monte Carlo modeling, eliminating the need for serial imaging. Our voxel-based approach demonstrates significant dose variations in prostate cancer patients under standard TRT with a one-size-fits-all radioligand dose, enabling pre-treatment dose personalization-a critical step toward precision radiot

SUBMITTER: Duong TT 

PROVIDER: S-EPMC12358388 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature